Skip to main content

Table 1 Overview of participation of brothers A and B in familial Alzheimer’s disease study

From: Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study

 

Year

Brother A

Brother B

Baseline

1995

NPA, MRI, CSF

NPA, CSF

+  1 year

1996

FDG-PET

FDG-PET

+  2 years

1997

NPA, MRI

NPA

+  3 years

1998

FDG-PET

FDG-PET

+  6 years

2001

NPA, MRI

NPA

+  11 years

2006

NPA, MRI, CSF, FDG-PET

NPA, CSF, FDG-PET

+  12 years

2007

Interview

 

+  13 years

2008

NPA, FDG-PET, PiB-PET

 

+  14 years

2009

NPA, MRI, FDG-PET, PiB-PET

NPA, MRI, FDG-PET, PiB-PET

+  16 years

2011

 

NPA

+  17 years

2012

 

PiB-PET

+  18 years

2013

 

NPA

+  20 years

2015

Interview, MMSE

Interview, MMSE

+  22 years

2017

 

NPA

  1. Abbreviations: CSF Cerebrospinal fluid sampling, FDG-PET [18F]fluorodeoxyglucose PET, MMSE Mini Mental State Examination, MRI Magnetic resonance imaging, NPA Neuropsychological assessment, PiB-PET [11C]Pittsburgh compound B positron emission tomography, MRI Magnetic resonance imaging
  2. The rows in the table indicate the year in which different examinations were performed. Brother A was diagnosed with mild cognitive impairment in 2006 and with dementia due to Alzheimer’s disease in 2007 (based on clinical symptoms)